|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berindan-Neagoe I, Monroig PC, Pasculli B
and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis
and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao XC, Yu Y, Hou LK, Sun XH, Ge J, Zhang
B and Wang X: miR-142-3p inhibits cancer cell proliferation by
targeting CDC25C. Cell Prolif. 49:58–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiao P and Liu WL: MiR-142-3p functions as
a potential tumor suppressor directly targeting HMGB1 in
non-small-cell lung carcinoma. Int J Clin Exp Pathol.
8:10800–10807. 2015.PubMed/NCBI
|
|
6
|
Su YH, Zhou Z, Yang KP, Wang XG, Zhu Y and
Fa XE: MIR-142-5p and miR-9 may be involved in squamous lung cancer
by regulating cell cycle related genes. Eur Rev Med Pharmacol Sci.
17:3213–3220. 2013.PubMed/NCBI
|
|
7
|
Colamaio M, Puca F, Ragozzino E, Gemei M,
Decaussin-Petrucci M, Aiello C, Bastos AU, Federico A, Chiappetta
G, Del Vecchio L, et al: miR-142-3p down-regulation contributes to
thyroid follicular tumorigenesis by targeting ASH1L and MLL1. J
Clin Endocrinol Metab. 100:E59–E69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen WW, Zeng Z, Zhu WX and Fu GH:
MiR-142-3p functions as a tumor suppressor by targeting CD133,
ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl).
91:989–1000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwickert A, Weghake E, Brüggemann K,
Engbers A, Brinkmann BF, Kemper B, Seggewiß J, Stock C, Ebnet K,
Kiesel L, et al: microRNA miR-142-3p inhibits breast cancer cell
invasiveness by synchronous targeting of WASL, integrin Alpha V,
and additional cytoskeletal elements. PLoS One. 10:e01439932015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Isobe T, Hisamori S, Hogan DJ, Zabala M,
Hendrickson DG, Dalerba P, Cai S, Scheeren F, Kuo AH, Sikandar SS,
et al: miR-142 regulates the tumorigenicity of human breast cancer
stem cells through the canonical WNT signaling pathway. Elife.
3:2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu G, Wang J, Jia Y, Shen F, Han W and
Kang Y: MiR-142-3p functions as a potential tumor suppressor in
human osteosarcoma by targeting HMGA1. Cell Physiol Biochem.
33:1329–1339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng Z, Ding M, Ni J, Song D, Huang J and
Wang J: MiR-142 acts as a tumor suppressor in osteosarcoma cell
lines by targeting Rac1. Oncol Rep. 33:1291–1299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang C and Youle RJ: The role of
mitochondria in apoptosis*. Annu Rev Genet. 43:95–118. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Young AP and Longmore GD: Differential
regulation of apoptotic genes by Rb in human versus mouse cells.
Oncogene. 23:2587–2599. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee YS and Dutta A: MicroRNAs: Small but
potent oncogenes or tumor suppressors. Curr Opin Investig Drugs.
7:560–564. 2006.PubMed/NCBI
|
|
20
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: Micrornas and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shrestha A, Mukhametshina RT, Taghizadeh
S, Vásquez-Pacheco E, Cabrera-Fuentes H, Rizvanov A, Mari B,
Carraro G and Bellusci S: MicroRNA-142 is a multifaceted regulator
in organogenesis, homeostasis, and disease. Dev Dyn. 246:285–290.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi X, Li J, Zhou C, Lv C and Tian M:
Mir-142-3p suppresses socs6 expression and promotes cell
proliferation in nasopharyngeal carcinoma. Cell Physiol Biochem.
36:1743–1752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chai S, Tong M, Ng KY, Kwan PS, Chan YP,
Fung TM, Lee TK, Wong N, Xie D, Yuan YF, et al: Regulatory role of
miR-142-3p on the functional hepatic cancer stem cell marker CD133.
Oncotarget. 5:5725–5735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sonda N, Simonato F, Peranzoni E, Calì B,
Bortoluzzi S, Bisognin A, Wang E, Marincola FM, Naldini L, Gentner
B, et al: miR-142-3p prevents macrophage differentiation during
cancer-induced myelopoiesis. Immunity. 38:1236–1249. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang
H, Hong M, Jiang T, Jiang Q, Lu J, et al: An oncogenic role of
miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by
targeting glucocorticoid receptor-α and cAMP/PKA pathways.
Leukemia. 26:769–777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu Y, Ji N, Wei W, Sun W, Gong X and Wang
X: MiR-142 modulates human pancreatic cancer proliferation and
invasion by targeting hypoxia-inducible factor 1 (HIF-1α) in the
tumor microenvironments. Biol Open. 6:252–259. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaduthanam S, Gade S, Meister M, Brase JC,
Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sültmann
H, et al: Serum miR-142-3p is associated with early relapse in
operable lung adenocarcinoma patients. Lung Cancer. 80:223–227.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ghanbari R, Mosakhani N, Asadi J, Nouraee
N, Mowla SJ, Yazdani Y, Mohamadkhani A, Poustchi H, Knuutila S and
Malekzadeh R: Downregulation of plasma mir-142-3p and mir-26a-5p in
patients with colorectal carcinoma. Iran J Cancer Prev.
8:e23292015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z,
Xia LY, Chen LR, Wang Y, Wang XZ, Bi LX, et al: miR-29a and
miR-142-3p downregulation and diagnostic implication in human acute
myeloid leukemia. Mol Biol Rep. 39:2713–2722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu S, Wei J, Wang F, Kong LY, Ling XY,
Nduom E, Gabrusiewicz K, Doucette T, Yang Y, Yaghi NK, et al:
Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy
against murine glioblastoma. J Natl Cancer Inst. 106:2014.
View Article : Google Scholar
|
|
31
|
Ding M, Hu J, Ni J, Zheng Z, Song D and
Wang J: Demethylation of microRNA-142 induced by demethylation
agents plays a suppressive role in osteosarcoma cells. Oncol Lett.
9:2261–2267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu K, Huang J, Ni J, Song D, Ding M, Wang
J, Huang X and Li W: MALAT1 promotes osteosarcoma development by
regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle.
16:578–587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu XX, Cao LY, Chen X, Xiao J, Zou Y and
Chen Q: PTEN inhibits cell proliferation, promotes cell apoptosis,
and induces cell cycle arrest via downregulating the
pi3K/akt/htertpathway in lung adenocarcinoma a549 Cells. Biomed Res
Int. 2016:24768422016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bermúdez BM, Goulielmaki E and
Papakonstanti EA: Focus on PTEN regulation. Front Oncol.
5:1662015.PubMed/NCBI
|
|
35
|
Schwartzbauer G and Robbins J: The tumor
suppressor gene PTEN can regulate cardiac hypertrophy and survival.
J Biol Chem. 276:35786–35793. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hellwinkel OJ, Müller J, Pollmann A and
Kabisch H: Osteosarcoma cell lines display variable individual
reactions on wildtype p53 and Rb tumour-suppressor transgenes. J
Gene Med. 7:407–419. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Iida K, Nobori T, Matsumine A, Isaka A,
Seto M, Shiraishi T and Uchida A: Effect of retinoblastoma tumor
suppressor gene expression on chemosensitivity of human
osteosarcoma cell lines. Oncol Rep. 10:1961–1965. 2003.PubMed/NCBI
|
|
38
|
Zhu Y, Li M, Wang X, Jin H, Liu S, Xu J
and Chen Q: Caspase cleavage of cytochrome c1 disrupts
mitochondrial function and enhances cytochrome c release. Cell Res.
22:127–141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF,
Huang WZ, Wang WS, Jiang TF, Wu BL, Li EM and Xu LY: MiR-142-3p as
a potential prognostic biomarker for esophageal squamous cell
carcinoma. J Surg Oncol. 105:175–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
